Literature DB >> 17085956

Pathobiology of classical Hodgkin lymphoma.

Alexandar Tzankov1, Stephan Dirnhofer.   

Abstract

The World Health Organization has acknowledged the malignant nature of classical Hodgkin lymphoma (cHL), which encompasses four histological subtypes. The diagnosis of cHL is based on the detection of malignant Hodgkin and Reed-Sternberg cells (HRSC) confirmed by immunophenotyping and the detection of growth patterns specific to each histological subtype. The pathologic HRSC arise from germinal center or immediate postgerminal cells that lack detectable immunoglobulin/B-cell antigen receptor expression, with a consequent loss of B-cell identity; very few cHL cases are of T-cell origin. To escape apoptosis, which normally occurs in B cells with nonfunctioning antigen receptor machinery, HRSC develop concurrent antiapoptotic mechanisms by activation of nuclear factor-kappaB or are rescued by Epstein-Barr virus infection. HRSC are characterized by a variable and inconstant immunophenotype, with a remarkable loss of lineage-specific cell antigens and expression of antigens of other cell lineages. The master plan of B-cell identity in HRSC is disturbed not only at the immunoglobulin expression level, but also at the transcriptional factor level. HRSC are further characterized by profound cell cycle deregulation with futile replication, multinucleation and poly- and aneuploidy. Here, we review pathobiological aspects of cHL with respect to lymphomagenesis and routine diagnostics.

Entities:  

Mesh:

Year:  2006        PMID: 17085956     DOI: 10.1159/000095558

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  6 in total

1.  Circulating clonotypic B cells in classic Hodgkin lymphoma.

Authors:  Richard J Jones; Christopher D Gocke; Yvette L Kasamon; Carole B Miller; Brandy Perkins; James P Barber; Milada S Vala; Jonathan M Gerber; Lan L Gellert; Mark Siedner; M Victor Lemas; Sarah Brennan; Richard F Ambinder; William Matsui
Journal:  Blood       Date:  2009-02-02       Impact factor: 22.113

Review 2.  Hodgkin lymphoma: an update on its biology with new insights into classification.

Authors:  Haresh Mani; Elaine S Jaffe
Journal:  Clin Lymphoma Myeloma       Date:  2009-06

3.  Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.

Authors:  Stefanie Kewitz; Martin S Staege
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

Review 4.  Molecular functions of metallothionein and its role in hematological malignancies.

Authors:  Shinichiro Takahashi
Journal:  J Hematol Oncol       Date:  2012-07-27       Impact factor: 17.388

5.  Expression and Regulation of the Endogenous Retrovirus 3 in Hodgkin's Lymphoma Cells.

Authors:  Stefanie Kewitz; Martin Sebastian Staege
Journal:  Front Oncol       Date:  2013-07-10       Impact factor: 6.244

Review 6.  Curcuma Contra Cancer? Curcumin and Hodgkin's Lymphoma.

Authors:  Stefanie Kewitz; Ines Volkmer; Martin S Staege
Journal:  Cancer Growth Metastasis       Date:  2013-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.